Does growth hormone treatment affect the risk of post-transplant renal cancer?

被引：26

作者：

Mehls, O

Wilton, P

Lilien, M

Berg, U

Broyer, M

Rizzoni, G

Waldherr, R

Opelz, G

机构：

[1] Univ Heidelberg, Childrens Hosp, Div Pediat Nephrol, D-69120 Heidelberg, Germany

[2] Pharmacia AB, KIGS KIMS Outcome Res, Stockholm, Sweden

[3] Wilhelmina Childrens Hosp, Utrecht, Netherlands

[4] Huddinge Univ Hosp, Karolinska Inst, Dept Pediat, Stockholm, Sweden

[5] Hop Necker Enfants Malad, Serv Nephrol Pediat, F-75743 Paris, France

[6] Osped Pediat Bambino Gesu, Div Nefrol & Dialisi, Rome, Italy

[7] Univ Heidelberg, Inst Pathol, D-6900 Heidelberg, Germany

[8] Univ Heidelberg, Dept Immunol, D-6900 Heidelberg, Germany

来源：

PEDIATRIC NEPHROLOGY | 2002年 / 17卷 / 12期

关键词：

growth hormone treatment; post-transplant renal cancer;

D O I：

10.1007/s00467-002-0962-7

中图分类号：

R72 [儿科学];

学科分类号：

100202 ;

摘要：

According to the analysis of the Collaborative Transplant Study (CTS), the incidence of renal carcinoma in patients with renal transplantation as well as with heart transplantation is significantly increased at any given patient age. The cumulative incidence 10 years after kidney transplantation is 185 per 100,000 patients in children below the age of 19 years at the time of transplantation. Age and inummosuppressive treatment seem to be the major risk factors. The majority of cancers develop within the native kidneys. Chronic transplant nephropathy and accelerated senescence may be further risk factors for the development of cancer within a kidney transplant. Growth hormone (GH) treatment could not be identified as an additional risk factor.

引用

页码：984 / 989

页数：6

共 26 条

[1] RENAL-CELL CARCINOMA DEVELOPING IN THE PEDIATRIC RECIPIENT OF AN ADULT CADAVERIC DONOR KIDNEY [J].